🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. BNT327, BNT323

    BioNTech SE

    Advanced Breast Cancer Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  2. BNT327, BNT324

    BioNTech SE

    Advanced Lung Cancer

    phase 2 small molecule active

    1 trial

  3. BNT327, DOCETAXEL

    BioNTech SE

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  4. BNT329

    BioNTech SE

    Advanced Solid Cancers

    phase 2 small molecule active

    1 trial

  5. BT8009, Zelenectide Pevedotin

    BICYCLE THERAPEUTICS

    NECTIN4 Amplified Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  6. BXCL701 plus Pembrolizumab

    BioXcel Therapeutics

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  7. Balstilimab, CR6086, CR6086

    Alphapharm Pty Ltd

    Pretreated mismatch-repair-proficient and microsatellite stable metastatic colorectal cancer, and other metastatic GI cancers

    phase 2 small molecule active

    1 trial

  8. Bavencio 20 mg/mL concentrate for solution for infusion

    Disc Medicine

    locally advanced urothelial cancer.

    phase 2 small molecule active

    1 trial

  9. Becotatug Vedotin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Penile Cancer

    phase 2 small molecule active

    1 trial

  10. Bemarituzumab

    Prime Medicine

    Gastric Cancer

    phase 2 mab completed

    1 trial

  11. Bendatax 6 mg/ ml, TAGRISSO 80 mg film-coated tablets, CISPLATIN, CARBOPLATIN, PEMETREXED, Cisplatin 1mg/ml Concentrate for Solution for Infusion, TAGRISSO 40 mg film-coated tablets, Armisarte 25 mg/ml concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, PACLITAXEL

    AstraZeneca AB

    Unresectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  12. Benmelstobart

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  13. Bevacizumab

    ONCOLYTICS BIOTECH INC

    Ras-mutated Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  14. Bevacizumab

    The First People's Hospital of Lianyungang

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  15. Bevacizumab

    BRIGHT MINDS BIOSCIENCES INC.

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  16. Bevacizumab combined with Oxaliplatin and TAS-102

    The First People's Hospital of Lianyungang

    Advanced Colorectal Cancer

    phase 2 small molecule active

    1 trial

  17. Bexarotene

    LIGAND PHARMACEUTICALS INC

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  18. Blood test

    Yang Xiaotian

    Cancer of Colon

    phase 2 other completed

    1 trial

  19. Braftovi 75 mg hard capsules, Erbitux 5 mg/mL solution for infusion

    CERO THERAPEUTICS HOLDINGS, INC.

    BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER

    phase 2 small molecule active

    1 trial

  20. Braftovi 75 mg hard capsules, Mektovi 15 mg film-coated tablets

    CERO THERAPEUTICS HOLDINGS, INC.

    BRAFV600E-mutant metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  21. Budenofalk 3mg magensaftresistente Hartkapseln, ALIMTA 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion., CISPLATINE ACCORD 1 mg/ml, solution à diluer pour perfusion, Carboplatin-GRY® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infu

    Hoffmann-La Roche

    Untreated Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  22. CABOMETYX 40 mg film-coated tablets, CABOMETYX 60 mg film-coated tablets, CABOMETYX 20 mg film-coated tablets

    Fondazione Telethon ETS

    Non small-cell lung cancer

    phase 2 small molecule active

    1 trial

  23. CALCIUM FOLINATE , MK-2870, -, -, PARACETAMOL , MK-1022, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CALCIUM LEVOFOLINATE , CAPECITABINE , -, MK-2870, FLUOROURACIL , OXALIPLATIN

    Merck Sharp and Dohme

    Gastroesophageal cancer

    phase 2 small molecule active

    1 trial

  24. CALCIUM FOLINATE, ivonescimab, CALCIUM LEVOFOLINATE, OXALIPLATIN, FLUOROURACIL

    Ningbo Cancer Hospital

    Advanced biliary tract cancer (BTC)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources